Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells 3,341 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,341 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the transaction, the general counsel now owns 58,057 shares of the company’s stock, valued at $2,687,458.53. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 20th, Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $50.11, for a total value of $154,539.24.

Tarsus Pharmaceuticals Trading Up 0.7 %

Shares of Tarsus Pharmaceuticals stock traded up $0.36 on Thursday, reaching $49.91. 618,361 shares of the company were exchanged, compared to its average volume of 639,768. The stock has a fifty day moving average price of $48.54 and a 200-day moving average price of $45.06. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.10 and a beta of 1.05. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TARS. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Barclays dropped their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. HC Wainwright reissued a “buy” rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Jefferies Financial Group boosted their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, Guggenheim reissued a “buy” rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $63.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals during the fourth quarter valued at $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $44,000. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $53,000. Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $166,000. Finally, HighTower Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $207,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.